Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2010 | Research

Evaluation of biodistribution and safety of adenovirus vector containing MDR1 in mice

Authors: ZhenZhen Zhao, Wei Liu, YuXi Su, Jin Zhu, GaiHuan Zheng, Qing Luo, XianQing Jin

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Abstract

Background

The aim of this study is to examine the safety and distribution of Ad-EGFP-MDR1, an adenovirus encoding human multidurg resistance gene (human MDR1), in the mice colon carcinoma model.

Methods

After bone marrow cells (BMCs) were infected with Ad-EGFP-MDR1, they were administered by intra bone marrow-bone marrow transplantation (IBM-BMT). Total adenovirus antibody and serum adenovirus neutralizing factor (SNF) were determined. Biodistribution of Ad-EGFP-MDR1 was detected by in situ hybridization and immunohistochemistry. The peripheral hematocyte white blood cell (WBC), haemoglobin (Hb), red blood cell (RBC) and platelet (Plt) counts were analyzed.

Results

Neither total adenovirus antibody nor SNF increased weeks after BMT. In situ hybridization and immunohistochemistry demonstrated concordant expression of human MDR1 and P-gp which were found in lung, intestine, kidney and BMCs after BMT, but not detected in liver, spleen, brain and tumor. No significant abnormality of the recovery hematocyte was observed on Day 30 after treatment.

Conclusion

The results indicate that IBM-BMT administration of a replication defective adenovirus is a feasible mode of delivery, allowing exogenous transference. The findings in this study are conducted for the future long-term studies of safety assessment of Ad-EGFP-MDR1.

Available only for authorised users

Neugut AI, Matasar M, Wang X, McBride R, Jacobson JS, Tsai WY, Grann VR, Hershman DL: Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006, 24 (15): 2368-2375. 10.1200/JCO.2005.04.5005.CrossRef

Gerardo R, Aniello T, Antonio R, Diodoro C, Carmine P, Giorgio R: A Phase Study of Irinotecan Alternated with a Weekly Schedule of Oxaliplat, High-Dose Leucovorin and 48 Hour Infusion 5-Fluorouracil in Patients with Advanced Colorectal Cancer. Oncology. 2004, 66: 371-378. 10.1159/000079485.CrossRef

Prete SP, Turriziani M, Massara MC, De Rossi A, Correale P, De Vecchis L, Torino F, Bonmassar L, Aquino A: Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy. J Exp Clin Cancer Res. 2008, 5-12. 10.1186/1756-9966-27-5. 27

André T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, et al: Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007, 25 (24): 3732-3738. 10.1200/JCO.2007.12.2234.CrossRef

Takahashi S, Ito Y, Hatake K, Sugimoto Y: Gene Therapy for Breast Cancer-Review of Clinical Gene Therapy Trials for Breast Cancer and MDR1 Gene Therapy Trial in Cancer Institute Hospital. Breast Cancer. 2006, 13 (1): 8-15. 10.2325/jbcs.13.8.CrossRef

Alexander C, Stefan P, Wolfram O, Axel RZ, Dieter KH, Klaus K, et al: Genetic Protection of Repopulating Hematopoietic Cells with an Improved MDR1-Retrovirus Allows Administration of Intensified Chemotherapy Following Stem Cell Transplantation in Mice. Int J Cancer. 2002, 98: 785-792. 10.1002/ijc.10206.CrossRef

Guo CB, Jin XQ: Chemoprotection Effect of Multidrug Resistance 1(MDR1) Gene Transfer to Hematopoietic Progenitor Cells and Engrafted in Mice with Cancer Allows Intensified Chemotherapy. Cancer Invest. 2006, 24 (7): 659-668. 10.1080/07357900600981299.CrossRef

Guo CB, Li YC, Jin XQ: Chemoprotection effect of retroviral vector encoding multidrug resistance 1 gene to allow intensified chemotherapy in vivo. Cancer Chemother Pharmacol. 2006, 58 (1): 40-49. 10.1007/s00280-005-0144-y.CrossRef

Taketoshi K, Muneo I, Hiroko H, Naoya I, Takashi E, Ryokei Og, et al: Intra-bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice. Blood. 2001, 97: 3292-3299. 10.1182/blood.V97.10.3292.CrossRef

10.

Wilson MW, Fraga CH, Fuller CE, Rodriguez-Galindo C, Mancini J, Hagedorn N, et al: Immunohistochemical Detection of Multidrug-Resistant Protein Expression in Retinoblastoma Treated by Primary Enucleation. Invest Ophthalmol Vis Sci. 2006, 47: 1269-1273. 10.1167/iovs.05-1321.CrossRef

11.

Wen SF, Chen Z, Nery J, Faha B: Characterization of adenovirus p21 gene transfer, biodistribution, and immune response after local ocular deliveryin New Zealand white rabbits. Experimental Eye Research. 2003, 77: 355-365. 10.1016/S0014-4835(03)00122-2.CrossRef

12.

Zhang H, Wen Z, Tan S, Li C, Lan S, Li J: Optimization of multidrug resistance 1 gene transfer confers chemoprotection to human hematopoietic cells engrafted in immunodeficient mice. Eur J Haematol. 2007, 78 (5): 432-439. 10.1111/j.1600-0609.2007.00824.x.CrossRef

13.

Haviernik P, Bunting KD: Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors. Curr Gene Ther. 2004, 4 (3): 263-276.CrossRef

14.

Rabik CA, Dolan ME: Molecular Mechanisms of Resistance and Toxicity Associated with Platinating Agents. Cancer Treat Rev. 2007, 33 (1): 9-23. 10.1016/j.ctrv.2006.09.006.CrossRef

15.

Gu DL, Nguyen T, Gonzalez AM, Printz MA, Pierce GF, Sosnowski BA, et al: Adenovirus Encoding Human Platelet-Derived Growth Factor-B Delivered in Collagen Exhibits Safety, Biodistribution, and Immunogenicity Profiles Favorable for Clinical Use. Mol Ther. 2004, 9 (5): 699-711. 10.1016/j.ymthe.2004.02.018.CrossRef

16.

Ni S, Bernt K, Gaggar A, Li ZY, Kiem HP, Lieber A: Evaluation of Biodistribution and Safety of Adenovirus Vectors Containing Group B Fibers after Intravenous Injection into Baboons. Hum Gene Ther. 2005, 16 (6): 664-677. 10.1089/hum.2005.16.664.CrossRef

17.

Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, et al: Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Therapy. 2005, 12: 437-445. 10.1038/sj.gt.3302436.CrossRef

18.

Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, Hutchins B, et al: Biological activities of a recombinant adenovirus p53(SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial. Cancer Gene Therapy. 2006, 13: 169-181. 10.1038/sj.cgt.7700870.CrossRef

19.

Plett PA, Frankovitz SM, Orschell CM: Distribution of marrow repopulating cells between bone marrow and spleen early after transplantation. Blood. 2003, 102 (6): 2285-2291. 10.1182/blood-2002-12-3742.CrossRef

20.

Zhong JF, Zhan Y, Anderson WF, Zhao Y: Murine hematopoietic stem cell distribution and proliferation in ablated and nonablated bone marrow transplantation. Blood. 2002, 100 (10): 3521-3526. 10.1182/blood-2002-04-1256.CrossRef

21.

Varnavski AN, Calcedo R, Bove M, Gao G, Wilson JM: Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice. Gene Therapy. 2005, 12: 427-436. 10.1038/sj.gt.3302347.CrossRef

22.

Schoggins JW, Falck-Pedersen E: Fiber and Penton Base Capsid Modifications Yield Diminished Adenovirus Type 5 Transduction and Proinflammatory Gene Expression with Retention of Antigen-Specific Humoral Immunity. J Virol. 2006, 80 (21): 10634-10644. 10.1128/JVI.01359-06.CrossRef

23.

Johnson M, Huyn S, Burton J, Sato M, Wu L: Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. Hum Gene Ther. 2006, 17 (12): 1262-1269. 10.1089/hum.2006.17.1262.CrossRef

24.

Plog MS, Guyre CA, Roberts BL, Goldberg M, St George JA, Perricone MA: Preclinical safety and biodistribution of Adenovirus-Based Cancer Vaccines After Intradermal Delivry. Hum Gene Ther. 2006, 17: 705-716. 10.1089/hum.2006.17.705.CrossRef

25.

Sakurai H, Sakurai F, Kawabata K, Sasaki T, Koizumi N, Huang H, et al: Comparison of gene expression efficiency and innate immune response induced by Ad vector and lipoplex. J Control Release. 2007, 117 (3): 430-437. 10.1016/j.jconrel.2006.11.030.CrossRef

26.

Veneziale RW, Bral CM, Sinha DP, Watkins RW, Cartwright ME, Rosenblum IY, et al: SCH 412499: biodistribution and safety of an adenovirus containing P21(WAF-1/CIP-1) following subconjunctival injection in Cynomolgus monkeys. Cutan Ocul Toxicol. 2007, 26 (2): 83-105. 10.1080/15569520701212167.CrossRef

27.

Nakamura K, Inaba M, Sugiura K, Yoshimura T, Kwon AH, Kamiyama Y, et al: Enhancement of allogeneic hematopoietic stem cell engraftment and prevention of GVHD by intrabone marrow bone marrow transplantation plus donor lymphocyte infusion. Stem Cells. 2004, 22: 125-134. 10.1634/stemcells.22-2-125.CrossRef

28.

Takahashi S, Aiba K, Ito Y, Hatake K, Nakane M, Kobayashi T, et al: Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients. Cancer Sci. 2007, 98: 1609-1616. 10.1111/j.1349-7006.2007.00571.x.CrossRef

Title: Evaluation of biodistribution and safety of adenovirus vector containing MDR1 in mice
Authors: ZhenZhen Zhao
Wei Liu
YuXi Su
Jin Zhu
GaiHuan Zheng
Qing Luo
XianQing Jin
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/1756-9966-29-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2010

MicroRNAs involved in neoplastic transformation of liver cancer stem cells

Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies

CIP2A expression is increased in prostate cancer

Functional study of the novel multidrug resistance gene HA117 and its comparison to multidrug resistance gene 1

Erratum to Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy

A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer